Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;15(10):1422-1433.
doi: 10.1111/jdi.14229. Epub 2024 Jun 29.

A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data

Affiliations

A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data

Yikuan Du et al. J Diabetes Investig. 2024 Oct.

Abstract

Aim/introduction: The recent adverse reactions associated with semaglutide have led the Food and Drug Administration (FDA) to issue a "black box warning", and it is necessary to analyze all reports of adverse reactions to improve the safety of its clinical use.

Materials and methods: Statistical analyses and signal mining were performed by obtaining the adverse event reports related to semaglutide in the FAERS database from the first quarter of 2018 to the fourth quarter of 2023. We used disproportionality and Bayesian analysis to examine clinical and demographic attributes, trends reported quarterly, and contrasts between two distinct indications (obesity and type 2 diabetes).

Results: We found 10 unexpected adverse signals related to "pancreatic cancer", "intestinal obstruction", "cholecystitis", and "polycystic ovary" and both the two different indications had the same serious adverse reaction events occurring.

Conclusions: This study identified many unexpected signals of serious adverse reactions, suggesting the importance of continuous post-marketing surveillance of semaglutide to understand its potential risks.

Keywords: Diabetes mellitus; Pharmacovigilance; Semaglutide.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant financial or non‐financial interests to disclose.

Approval of the research protocol: N/A.

Informed consent: N/A.

Registry and the registration no. of the study/trial: N/A.

Animal studies: N/A.

Figures

Figure 1
Figure 1
The flow diagram of selecting semaglutide‐related adverse events from the FAERS database.
Figure 2
Figure 2
The number of reported adverse events and gender differences in semaglutide during 2018 Q1–2023 Q2.
Figure 3
Figure 3
The bar plot shows a statistical graph of the 21 SOCs associated with case reports of semaglutide adverse events. Percentage values labeled in the figure represent the proportion of cases in which semaglutide had an adverse event in each SOC. The different colors represent the signal strength (IC025), the redder the color, the higher the signal strength.
Figure 4
Figure 4
The radial plot shows 36 common and new preferred terms in the top 6 signal strength of SOCs of semaglutide ranked by IC025. Different colors represent different SOCs. The number marked in the graph represents the signal strength (IC025), and the higher the number, the higher the signal strength.

Similar articles

Cited by

References

    1. GBD 2021 Diabetes Collaborators . Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021. Lancet 2023; 402: 203–234. - PMC - PubMed
    1. Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet 2017; 389: 2239–2251. - PubMed
    1. Piché ME, Tchernof A, Després JP. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ Res 2020; 126: 1477–1500. - PubMed
    1. GBD 2019 Risk Factors Collaborators . Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396: 1223–1249. - PMC - PubMed
    1. Gray SM, Hoselton AL, Krishna R, et al. GLP‐1 receptor blockade reduces stimulated insulin secretion in fasted subjects with low circulating GLP‐1. J Clin Endocrinol Metab 2022; 107: 2500–2510. - PMC - PubMed

Grants and funding